- Revenue Growth: Q2 2024 revenue of $20.7 million, up 58% year-over-year.
- Improved Profitability: Net loss narrowed by 73% to $1.1 million, with adjusted EBITDA reaching $0.1 million.
- Milestone Achievements: Obtained CE Medical certification for the UK and Europe, launching Dream Sock across major European markets.
“While pleased with our advancements across our business, we are not resting and plan to continually lay the regulatory groundwork for additional commercial expansion in both our home US market and abroad. A prime example of this comes on the heels of our groundbreaking FDA clearances in 2023, and during the quarter, we announced medical certification and product introductions in both the UK and EU markets. In short order, we have dramatically expanded our market access at a time when we have resumed our top line growth trajectory. Further, we kicked off Q3 with record-breaking results for Prime Day on both Amazon and OwletCare.com. We see Owlet as being well-positioned for long-term success, and I’m excited to lead our dynamic company into the next phase of its growth.”
Kurt Workman, CEO